Renaissance Technologies LLC Grows Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Renaissance Technologies LLC increased its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 67.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 101,248 shares of the company's stock after purchasing an additional 40,800 shares during the quarter. Renaissance Technologies LLC owned 0.21% of Mirum Pharmaceuticals worth $4,187,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the business. Barclays PLC raised its holdings in Mirum Pharmaceuticals by 4.6% during the 3rd quarter. Barclays PLC now owns 245,918 shares of the company's stock valued at $9,592,000 after buying an additional 10,824 shares during the last quarter. Geode Capital Management LLC raised its position in Mirum Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company's stock valued at $36,519,000 after purchasing an additional 29,017 shares during the last quarter. Lord Abbett & CO. LLC purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter worth approximately $28,913,000. Hennion & Walsh Asset Management Inc. lifted its stake in Mirum Pharmaceuticals by 25.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company's stock worth $6,021,000 after acquiring an additional 29,545 shares during the period. Finally, Avanza Fonder AB bought a new stake in Mirum Pharmaceuticals in the fourth quarter valued at $189,000.

Insider Activity at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 27,279 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $1,206,004.59. Following the transaction, the chief executive officer now owns 138,641 shares in the company, valued at $6,129,318.61. This trade represents a 16.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $126,673.94. Following the completion of the sale, the chief operating officer now directly owns 26,961 shares in the company, valued at $1,300,059.42. This represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 105,557 shares of company stock valued at $4,726,040. 22.87% of the stock is owned by company insiders.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock traded up $0.37 during mid-day trading on Friday, reaching $40.84. 84,593 shares of the company traded hands, compared to its average volume of 522,442. The firm's fifty day moving average is $44.36 and its two-hundred day moving average is $43.96. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of -20.18 and a beta of 1.00. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). The business had revenue of $99.41 million for the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. On average, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on MIRM shares. Robert W. Baird lifted their target price on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. HC Wainwright lifted their price objective on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $58.20.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.